New drug combo aims to shrink tumors before esophageal cancer surgery
NCT ID NCT06869213
Summary
This study is testing whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy helps people with a type of esophageal cancer that can be removed by surgery. The goal is to shrink the tumor before the operation and then continue the immunotherapy afterward to try to keep the cancer from coming back. Researchers will enroll 30 patients to see how well this approach works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER (ESC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.